Pfizer earnings miss analyst expectations

Pharmaceutical giant Pfizer announced fourth-quarter earnings that missed analyst expectations Tuesday following a pair of recent acquisitions.

Net income in the fourth quarter was $775 million, compared with a loss of $172 million in the year-ago period. That translated into 47 cents per share, three cents below analyst expectations.

Revenues were $13.6 billion, down three percent from the year-ago period.

Pfizer, which completed purchases of Medivation and Anacor last year, said results were dented in part by patent expirations on popular drugs and the strong dollar.

Pfizer's best-known drugs include the sexual dysfunction medication Viagra, the cancer drug Ibrance and the pain drug Lyrica.